Principal Investigator
Co- Principal Investigator
The overall goal of the City of Hope Lymphoma Specialized Program of Research Excellence (SPORE) is to develop translational studies to improve the detection and therapy of Hodgkin’s and non-Hodgkin’s Lymphoma. This grant consists of four translational research projects and five cores developing novel approaches that are derived from molecular and immunologic studies of T-cell and antibody based therapies. An important theme of the translational studies in this grant is to develop lymphoma therapies that will reduce toxicities associated with current treatment regimens for Hodgkin’s and non-Hodgkin’s Lymphoma which can then be translated to the older patient population.
The major goal of Project 1 is to develop anti-CD30 based radioimmunotherapy for both Hodgkin’s and CD30+ non-Hodgkin’s Lymphoma.
Project 2 will study the effectiveness of cellular immunotherapy to eradicate B-lineage lymphoma using genetically modified CD4+ and CD8+ T-cells expressing a CD19-specific chimeric immunoreceptor, which recognizes CD19 malignant B-cells.
Because epidemiologic studies indicate that stem cell damage from pretransplant therapeutic exposures may play a role in the development of myelodysplasia, Project 3 will longitudinally study a population of patients with Hodgkin’s and non-Hodgkin’s Lymphoma to investigate the cellular and molecular factors that are predictive for development of myelodysplasia, and to determine the molecular sequence of events that lead to myelodysplasia.
In Project 4, investigators will develop molecularly engineered constructs for anti-CD20 directed therapeutics to improve imaging, radioimmunotherapy, and novel immunocytokines for the treatment of patients with CD20+ lymphoma. An important component of this project will be to delineate the immunologic effector mechanisms operative in immunocytokine-mediate anti-lymphoma in vivo activity.
This Lymphoma SPORE also supports a Developmental Research Program and a Career Development Program to foster the advancement of pilot translational research projects and young investigators focused on lymphoma.
